I-Chen Chen Selected Research

Alkaloids

6/2021

Protective Effect of Piplartine against LPS-Induced Sepsis through Attenuating the MAPKs/NF-κB Signaling Pathway and NLRP3 Inflammasome Activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

I-Chen Chen Research Topics

Disease

4	Inflammation (Inflammations) 10/2021 - 01/2019
4	Pulmonary Hypertension 01/2021 - 01/2011
4	Pulmonary Arterial Hypertension 01/2021 - 11/2015
3	Sepsis (Septicemia) 06/2021 - 11/2015
3	Vascular Remodeling 01/2021 - 01/2017
3	Left Ventricular Dysfunction 01/2020 - 01/2011
2	Hypoxia (Hypoxemia) 04/2022 - 01/2019
2	Congenital Heart Defects (Congenital Heart Defect) 01/2022 - 11/2015
2	Fibrosis (Cirrhosis) 01/2022 - 03/2018
2	Congenital Abnormalities (Deformity) 01/2022 - 01/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2020
2	Oropharyngeal Neoplasms 11/2019 - 05/2015
2	Neuromuscular Diseases (Neuromuscular Disease) 01/2019 - 06/2014
2	Respiratory Insufficiency (Respiratory Failure) 01/2019 - 06/2014
2	Neoplasms (Cancer) 10/2014 - 11/2007
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022
1	Neural Tube Defects (Exencephaly) 01/2022
1	Idiopathic Pulmonary Fibrosis 01/2022
1	Hypertension (High Blood Pressure) 11/2021
1	Wounds and Injuries (Trauma) 11/2021
1	Acute Lung Injury 10/2021
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 06/2021
1	Infections 01/2021
1	Heart Failure 01/2021
1	Cardiomyopathies (Cardiomyopathy) 01/2021
1	Hematoma 01/2019
1	False Aneurysm (Pseudoaneurysm) 01/2019
1	Hyperkalemia 01/2019
1	Shock 01/2019
1	Hemorrhage 01/2019
1	Hypertrophy 03/2018
1	Familial Primary Pulmonary Hypertension 01/2018
1	Critical Illness (Critically Ill) 01/2018
1	Pleural Effusion (Pleural Effusions) 01/2017
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2016

Drug/Important Bio-Agent (IBA)

2	Proteasome InhibitorsIBA 04/2022 - 01/2022
2	InflammasomesIBA 06/2021 - 01/2021
2	diminazene aceturateIBA 01/2021 - 01/2020
2	Vasodilator Agents (Vasodilators)IBA 01/2021 - 01/2018
2	AngiotensinsIBA 01/2021 - 01/2020
2	Angiotensin-Converting Enzyme 2IBA 01/2021 - 01/2020
2	Endothelin-1 (Endothelin 1)IBA 01/2019 - 01/2017
2	MonocrotalineIBA 03/2018 - 01/2018
2	L-902688IBA 03/2018 - 01/2018
2	rho-Associated KinasesIBA 01/2017 - 01/2011
1	marizomibIBA 04/2022
1	Bortezomib (Velcade)FDA Link 04/2022
1	Extracellular Matrix ProteinsIBA 01/2022
1	ORALIT (ORS)IBA 01/2022
1	Metalloproteases (Metalloproteinases)IBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 10/2021
1	corylinIBA 10/2021
1	CytokinesIBA 10/2021
1	Proteins (Proteins, Gene)FDA Link 10/2021
1	Hematoxylin (Haematoxylon)IBA 10/2021
1	AlkaloidsIBA 06/2021
1	piperlongumineIBA 06/2021
1	Biological ProductsIBA 06/2021
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2021
1	zerumboneIBA 01/2021
1	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2021
1	Valsartan (Vals)FDA Link 01/2021
1	sacubitrilIBA 01/2021
1	MycotoxinsIBA 01/2021
1	LipopolysaccharidesIBA 01/2021
1	Neprilysin (Neutral Endopeptidase)IBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Vasoconstrictor AgentsIBA 01/2021
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2020
1	Polycyclic Aromatic Hydrocarbons (Polynuclear Aromatic Hydrocarbons)IBA 01/2020
1	Peptides (Polypeptides)IBA 01/2019
1	ChemokinesIBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	CollagenIBA 03/2018
1	Indicators and Reagents (Reagents)IBA 01/2018
1	ProstaglandinsIBA 01/2018
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2018
1	Epoprostenol ReceptorsIBA 01/2018
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2018
1	Oxidoreductases (Dehydrogenase)IBA 01/2017
1	Phosphotransferases (Kinase)IBA 01/2017
1	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 01/2017
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2017
1	Simvastatin (Zocor)FDA LinkGeneric 01/2017
1	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2017
1	Coenzyme A (CoA)IBA 01/2017

Therapy/Procedure

6	Therapeutics 01/2021 - 01/2010
2	Free Tissue Flaps 11/2019 - 05/2015
2	Catheters 01/2019 - 01/2010
2	Noninvasive Ventilation 01/2019 - 06/2014
2	Length of Stay 01/2017 - 02/2010
1	Mediterranean Diet 11/2021
1	Debridement 11/2021
1	Breast Implants (Breast Implant) 06/2021
1	Pneumonectomy (Lung Volume Reduction) 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Renal Dialysis (Hemodialysis) 01/2019
1	Thoracotomy 01/2017
1	Critical Care (Surgical Intensive Care) 01/2016